JPMorgan analyst Cory Kasimov believes the recent selloff in shares of bluebird bio (BLUE) has brought a "highly compelling opportunity" ahead of the data readouts coming in Q4. After hosting investor meetings with the company's CEO Nick Leschly and CFO Jim DeTore, Kasimov reiterates an Overweight rating on the stock. Competition in the sickle cell disease space was a popular topic following the recent initial public offering by Global Blood Therapeutics (GBT), Kasimov tells investors in a research note. However, bluebird management finds it too early for a meaningful discussion on competitive profiles given the early stage of data from both companies, the analyst points out. Kasimov has an Overweight rating on bluebird bio with a $244 price target. The stock closed yesterday at $127.01.